Chroma Peptides: tanning shares the controls

The erectile-function trial

The most revealing paper for a site named Chroma measures erections. In a 1998 double-blind crossover study of Melanotan II, 10 men with psychogenic erectile dysfunction received the compound and placebo. Clinically apparent erections occurred in 8 of 10 men; mean duration of greater-than-80% tip rigidity was 38.0 minutes with Melanotan II versus 3.0 minutes with placebo.

Sexual function was the intended subject of that trial. The molecule gives this paper its place here: a synthetic analogue of a pigment-signalling hormone, already doing something that a reader arriving for a tan might never have put in the same category. The study also recorded transient nausea, stretching and yawning that required no treatment.

The trial set out to measure erections. Calling the molecule a pigment peptide still leaves that activity in the picture.

In a print, colour separation pulls a single image apart into layers. The biological version is harder: a non-selective hormone analogue engages related receptors with different jobs, and a skin-colour claim needs an account of those other jobs too.

Melanocortin selectivity

Melanotan II acts across the melanocortin receptor family. MC1R on pigment cells leads toward melanin production; MC3R and MC4R participate in appetite, energy balance and sexual motivation. The history of melanocortin therapeutics follows the family into distinct clinical programmes, while an appetite experiment in male mice examined the compound in a brain region involved in reward.

I approach a tanning claim through selectivity: how narrowly the compound acts. A visible skin change gives no measure of its activity in the rest of the body. Melanotan II has no approved use anywhere, and its small early human trials leave long-term safety unanswered. The Melanotan II page follows the receptor findings, pigment changes and serious adverse-event record.

Copper and the blue complex

The blue of GHK-Cu comes from the copper complex itself. Its research concerns copper handling, connective tissue and delivery into skin. In the 2025 review of topical GHK, the practical problem is a water-loving peptide meeting the outer skin barrier. Small topical studies address appearance; a separate GHK combination trial measured hair count.

I give copper its own space because a coloured substance and a pigment-signalling analogue answer such different biological questions. Copper Tripeptide-1 has permitted topical cosmetic use, while systemic GHK-Cu has no approved pharmaceutical indication or validated human pharmacokinetic basis. The GHK-Cu notes move from the material's chemistry to the measurements.

The GLOW mixture

GLOW usually combines GHK-Cu, BPC-157 and TB-500. Here the argument goes in the other direction: several mechanisms are gathered into one mixture, with no controlled trial showing how they behave together. A review covering these unapproved peptides describes favourable animal findings alongside scarce rigorous human safety data and potential for serious harm.

The word “glow” makes the desired endpoint sound simple. The separate ingredient papers give me no measured cosmetic benefit, combined exposure pattern or reliable synergy for the mixture. The blend page examines that combination hypothesis, and the comparison puts each claim beside its actual experiment.

Chroma Peptides in the UK?

This site has no shop or laboratory service, in the UK or elsewhere. Chroma Peptides is the name of these research notes. An enquiry about a product described as Chroma Labs Peptides needs information about that particular product and its source; I cannot authenticate it from a similar name.

There is more on what this site covers, and a reading list for the papers discussed here.